{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASPR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASPR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASPR\",,,,,undefined,":{"symbol":"ASPR","market":"US","secType":"STK","nameCN":"Adsouth Partners, Inc.","latestPrice":0.0006,"timestamp":1742846400000,"preClose":0.0006,"halted":0,"volume":0,"delay":15,"changeRate":0,"change":0,"floatShares":10442039,"shares":141830741,"eps":-0.656674,"lyrEps":-0.262582,"pbRate":-0.1,"amount":0,"amplitude":0,"volumeRatio":0.07258751032824201,"dividePrice":0,"prevYearClose":0.0006,"fiveDayClose":0.0006,"twentyDayClose":0.0006},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASPR\",,,,,undefined,":{"symbol":"ASPR","floatShares":10442039,"roa":"-21.86%","roe":"-292.97%","lyrEps":-0.262582,"volumeRatio":0.07258751032824201,"shares":141830741,"dividePrice":0,"high":0.0006,"amplitude":0,"preClose":0.0006,"low":0.0006,"week52Low":0.0002,"pbRate":"-0.10","psRate":"0.01","week52High":0.0006,"institutionHeld":0,"latestPrice":0.0006,"eps":-0.656674,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.656674,"open":0.0006,"prevYearClose":0.0006,"prevWeekClose":0.0006,"prevMonthClose":0.0006,"prevQuarterClose":0.0006,"fiveDayClose":0.0006,"twentyDayClose":0.0006,"sixtyDayClose":0.0006},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASPR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASPR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASPR\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ASPR\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASPR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514410660","title":"OraSure Reports Fourth Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514410660","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514410660?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:05","pubTimestamp":1740517500,"startTime":"0","endTime":"0","summary":"BETHLEHEM, Pa., Feb.  25, 2025  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3032436/11732/en/OraSure-Reports-Fourth-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","BK4139","BK4585","BNTX","BK4588","OSUR","BK4551","NG","BK4198","BK4548","HHS","BK4568","BK4535","BK4009","ASPR"],"gpt_icon":0},{"id":"2508458639","title":"RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2508458639","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508458639?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:00","pubTimestamp":1738670400,"startTime":"0","endTime":"0","summary":"The 80-patientplacebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer , testing the potentially enhancing effect of opaganib in patients with a poor prognosis. The study is being financially supported by Bayer  and the Ramsay Hospital Research Foundation, and will be led by Professor Lisa Horvath from Chris O'Brien Lifehouse and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group . The study will utilize a companion lipid biomarker test  to select mCRPC patients who have a poor prognosis due to standard of care treatment and who may benefit from an opaganib + darolutamide combination treatment approach. Primary endpoint will be improved 12-month radiographic progression-free survival . Prostate cancer  is the second most diagnosed cancer in the world, with around 1.5 million new cases per year, causing almost 400,000 deaths. People with mC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-announces-initiation-phase-2-120000083.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-announces-initiation-phase-2-120000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","BK4211","BK4192","BK4007","IE0031619046.USD","RDHL","BK4195","AR","BK4157","PFS","BK4165","ASPR","AEIS","PC","IE00B66KJ199.SGD","ADT","BK4213","IE00B7SZL793.SGD","BK4209","BK4009"],"gpt_icon":0},{"id":"2505523201","title":"Why Is Moderna Stock Trading Higher On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505523201","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505523201?lang=en_us&edition=fundamental","pubTime":"2025-01-22 01:08","pubTimestamp":1737479319,"startTime":"0","endTime":"0","summary":"Tuesday, Moderna Inc  stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.On Friday, Moderna announced ongoing support from the U.S. Department of Health and Human Services  to accelerate the development of mRNA-based pandemic influenza vaccines.The award was made through the Rapid Response Partnership Vehicle  Consortium with funding from the Biomedical Advanced Research and Development Authority , part of the HHS Administration for Strategic Preparedness and Response .Also Read: Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination. The project will support the late-stage development and licensure of pre-pandemic mRNA-based vaccines. The agreement will also expand clinical studies for up to five additional subtypes of pandemic influenza.In 2023, Moderna commenced a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine  in healthy adults 18 years and older","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-moderna-stock-trading-higher-170839302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASPR","BK4534","BK4551","BK4532","BK4585","BK4501","BK4139","BK4533","HHS","BK4588","BK4548","BK4568","MRNA","BK4009"],"gpt_icon":1},{"id":"2503669705","title":"Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503669705","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503669705?lang=en_us&edition=fundamental","pubTime":"2025-01-14 08:55","pubTimestamp":1736816100,"startTime":"0","endTime":"0","summary":"Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the tr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3008969/25416/en/Vaxart-Announces-Favorable-DSMB-Review-of-Sentinel-Cohort-from-COVID-19-Phase-2b-Clinical-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4009","BK4588","HHS","BK4535","ASPR","BK4568","BNTX","BK4585","BK4551","BK4139","BK4548"],"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":26}]}}